Citation of this article
Corresponding Author of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (3778)
All Articles published online
|
Jul 21, 2006 (publication date) through Nov 29, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Assy N, Grozovski M, Bersudsky I, Szvalb S, Hussein O. Effect of insulin-sensitizing agents in combination with ezetimibe, and valsartan in rats with non-alcoholic fatty liver disease. World J Gastroenterol 2006; 12(27): 4369-4376 [PMID: 16865780 DOI: 10.3748/wjg.v12.i27.4369] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v12/i27/4369.htm |
| Number | Citing Articles |
| 1 |
Jenna L. Betters, Liqing Yu. NPC1L1 and cholesterol transport. FEBS Letters 2010; 584(13): 2740 doi: 10.1016/j.febslet.2010.03.030
|
| 2 |
Shuqin Zheng, Lizbeth Hoos, John Cook, Glen Tetzloff, Harry Davis, Margaret van Heek, Joyce J. Hwa. Ezetimibe improves high fat and cholesterol diet-induced non-alcoholic fatty liver disease in mice. European Journal of Pharmacology 2008; 584(1): 118 doi: 10.1016/j.ejphar.2008.01.045
|
| 3 |
Ying Ding, Min Song, Jia Han, Qi Yu, Erjia Yan, Lili Lin, Tamy Chambers, Judit Bar-Ilan. Entitymetrics: Measuring the Impact of Entities. PLoS ONE 2013; 8(8): e71416 doi: 10.1371/journal.pone.0071416
|
| 4 |
Zobair M. Younossi, Li Zheng, Maria Stepanova, Linda Henry, Chapy Venkatesan, Alita Mishra. Trends in Outpatient Resource Utilizations and Outcomes for Medicare Beneficiaries With Nonalcoholic Fatty Liver Disease. Journal of Clinical Gastroenterology 2015; 49(3): 222 doi: 10.1097/MCG.0000000000000071
|
| 5 |
Jelske N. van der Veen, Susanne Lingrell, Xia Gao, Abhijit Takawale, Zamaneh Kassiri, Dennis E. Vance, René L. Jacobs. Fenofibrate, but not ezetimibe, prevents fatty liver disease in mice lacking phosphatidylethanolamine N-methyltransferase. Journal of Lipid Research 2017; 58(4): 656 doi: 10.1194/jlr.M070631
|
| 6 |
Fatima Kasbi-Chadli, Morgan Treguier, François Briand, Thierry Sulpice, Khadija Ouguerram. Ezetimibe Enhances Macrophage-to-Feces Reverse Cholesterol Transport in Golden Syrian Hamsters Fed a High-Cholesterol Diet. Journal of Pharmacology and Experimental Therapeutics 2020; 375(2): 349 doi: 10.1124/jpet.120.000062
|
| 7 |
Ilias D. Vachliotis, Stergios A. Polyzos. The Role of Tumor Necrosis Factor-Alpha in the Pathogenesis and Treatment of Nonalcoholic Fatty Liver Disease. Current Obesity Reports 2023; 12(3): 191 doi: 10.1007/s13679-023-00519-y
|
| 8 |
Toshiyuki Oishi, Shuji Terai, Shinya Kuwashiro, Koichi Fujisawa, Toshihiko Matsumoto, Hiroshi Nishina, Isao Sakaida. Ezetimibe reduces fatty acid quantity in liver and decreased inflammatory cell infiltration and improved NASH in medaka model. Biochemical and Biophysical Research Communications 2012; 422(1): 22 doi: 10.1016/j.bbrc.2012.04.087
|
| 9 |
Chongli Xu, Yu Liu, Yuchen Gong, Xinping Duan, Xiaochun Tang, Mingjun Zhang, Daxin Pang, Liqing Yu, Hong Wei, Hongsheng Ouyang. Overexpression of NPC1L1 in the livers of transgenic Bama miniature pigs accelerates lipid peroxidation. Genes & Genomics 2015; 37(2): 183 doi: 10.1007/s13258-014-0235-4
|
| 10 |
Shoichiro Terunuma, Noriko Kumata, Kyoichi Osada. Ezetimibe Impairs Uptake of Dietary Cholesterol Oxidation Products and Reduces Alterations in Hepatic Cholesterol Metabolism and Antioxidant Function in Rats. Lipids 2013; 48(6): 587 doi: 10.1007/s11745-013-3790-6
|
| 11 |
Lin Jia, Jenna L. Betters, Liqing Yu. Niemann-Pick C1-Like 1 (NPC1L1) Protein in Intestinal and Hepatic Cholesterol Transport. Annual Review of Physiology 2011; 73(1): 239 doi: 10.1146/annurev-physiol-012110-142233
|
| 12 |
Kaori Kikuchi, Uru Nezu, Koji Inazumi, Takashi Miyazaki, Kanako Ono, Kazuki Orime, Jun Shirakawa, Koichiro Sato, Hirofumi Koike, Tadashi Wakasugi, Misako Sato, Chihiro Kawakami, Shinichiro Watanabe, Tadashi Yamakawa, Yasuo Terauchi. Double-Blind Randomized Clinical Trial of the Effects of Ezetimibe on Postprandial Hyperlipidaemia and Hyperglycaemia. Journal of Atherosclerosis and Thrombosis 2012; 19(12): 1093 doi: 10.5551/jat.12427
|
| 13 |
Tatjána Ábel, János Fehér, Elek Dinya, Mohamed Gamal Eldin, Attila Kovács. Efficacy and safety of ezetimibe/simvastatin combination therapy in patients with type 2 diabetes and nonalcoholic fatty liver disease. Orvosi Hetilap 2009; 150(21): 989 doi: 10.1556/oh.2009.28624
|
| 14 |
Tomohiro Ogawa, Hideki Fujii, Katsutoshi Yoshizato, Norifumi Kawada. A Human-Type Nonalcoholic Steatohepatitis Model with Advanced Fibrosis in Rabbits. The American Journal of Pathology 2010; 177(1): 153 doi: 10.2353/ajpath.2010.090895
|
| 15 |
M. H. Ahmed, C. D. Byrne. Potential therapeutic uses for ezetimibe beyond lowering LDL‐c to decrease cardiovascular events. Diabetes, Obesity and Metabolism 2010; 12(11): 958 doi: 10.1111/j.1463-1326.2010.01261.x
|
| 16 |
Lin Jia, Yinyan Ma, Shunxing Rong, Jenna L. Betters, Ping Xie, Soonkyu Chung, Nanping Wang, Weiqing Tang, Liqing Yu. Niemann-Pick C1-Like 1 deletion in mice prevents high-fat diet-induced fatty liver by reducing lipogenesis. Journal of Lipid Research 2010; 51(11): 3135 doi: 10.1194/jlr.M006353
|
| 17 |
Tracey G. Simon, Kathleen E. Corey, Raymond T. Chung, Robert Giugliano. Cardiovascular Risk Reduction in Patients with Nonalcoholic Fatty Liver Disease: The Potential Role of Ezetimibe. Digestive Diseases and Sciences 2016; 61(12): 3425 doi: 10.1007/s10620-016-4330-z
|
| 18 |
Peter Fraunberger, Elisabeth Gröne, Hermann-Josef Gröne, Heinz Drexel, Autar K. Walli. Ezetimibe reduces cholesterol content and NF-kappaB activation in liver but not in intestinal tissue in guinea pigs. Journal of Inflammation 2017; 14(1) doi: 10.1186/s12950-017-0150-y
|
| 19 |
Sung-Woo Park. Intestinal and Hepatic Niemann-Pick C1-Like 1. Diabetes & Metabolism Journal 2013; 37(4): 240 doi: 10.4093/dmj.2013.37.4.240
|
| 20 |
Milan Gupta, Paul E Szmitko, Michelle Tsigoulis, Manoela F B Braga, Mahesh Kajil, Sheriar Herjikaka, Adrian Quan, Hwee Teoh, Subodh Verma. Effects of Ezetimibe Add-on to Statin Therapy on Adipokine Production in Patients With Metabolic Syndrome and Stable Vascular Disease. Journal of Cardiovascular Pharmacology 2010; 56(3): 241 doi: 10.1097/FJC.0b013e3181e7fd74
|
| 21 |
Manal F. Abdelmalek, Anna Mae Diehl. Nonalcoholic Fatty Liver Disease as a Complication of Insulin Resistance. Medical Clinics of North America 2007; 91(6): 1125 doi: 10.1016/j.mcna.2007.06.001
|
| 22 |
Nalini Sodum, Gautam Kumar, Sree Lalitha Bojja, Nitesh Kumar, C. Mallikarjuna Rao. Epigenetics in NAFLD/NASH: Targets and therapy. Pharmacological Research 2021; 167: 105484 doi: 10.1016/j.phrs.2021.105484
|
| 23 |
Shivakumar Chitturi. Review: Treatment options for nonalcoholic fatty liver disease. Therapeutic Advances in Gastroenterology 2008; 1(3): 173 doi: 10.1177/1756283X08096951
|
| 24 |
J. Mark Brown, Liqing Yu. Cholesterol Binding and Cholesterol Transport Proteins:. Subcellular Biochemistry 2010; 51: 337 doi: 10.1007/978-90-481-8622-8_12
|
| 25 |
Sukhpreet Singh, Natalia A Osna, Kusum K Kharbanda. Treatment options for alcoholic and non-alcoholic fatty liver disease: A review. World Journal of Gastroenterology 2017; 23(36): 6549-6570 doi: 10.3748/wjg.v23.i36.6549
|
| 26 |
Mohamed H. Ahmed, Christopher D. Byrne. Ezetimibe as a potential treatment for non-alcoholic fatty liver disease: is the intestine a modulator of hepatic insulin sensitivity and hepatic fat accumulation?. Drug Discovery Today 2010; 15(15-16): 590 doi: 10.1016/j.drudis.2010.06.007
|
| 27 |
Lin Jia, Yinyan Ma, George Liu, Liqing Yu. Dietary cholesterol reverses resistance to diet-induced weight gain in mice lacking Niemann-Pick C1-Like 1. Journal of Lipid Research 2010; 51(10): 3024 doi: 10.1194/jlr.M008599
|
| 28 |
Juan Li, Xingping Shen. Effect of rosiglitazone on inflammatory cytokines and oxidative stress after intensive insulin therapy in patients with newly diagnosed type 2 diabetes. Diabetology & Metabolic Syndrome 2019; 11(1) doi: 10.1186/s13098-019-0432-z
|
| 29 |
Li Qin, Yun-Bo Yang, Yi-Xin Yang, Yong-Zhen Gong, Xiao-Ling Li, Gui-Yuan Li, Hong-Dan Luo, Xue-Jiao Xie, Xi-Long Zheng, Duan-Fang Liao. Inhibition of Smooth Muscle Cell Proliferation by Ezetimibe via the Cyclin D1-MAPK Pathway. Journal of Pharmacological Sciences 2014; 125(3): 283 doi: 10.1254/jphs.13239FP
|
| 30 |
Beniamino PALMIERI, Veronica CORAZZARI, Diana G. PANARIELLO BRASILE, Vincenzo SANGIOVANNI, Maria VADALÀ. Hepatic steatosis integrated approach: nutritional guidelines and joined nutraceutical administration. Minerva Gastroenterologica e Dietologica 2021; 66(4) doi: 10.23736/S1121-421X.20.02738-5
|
| 31 |
Hai-Ning Wang, Yan-Rong Wang, Guo-Qiang Liu, Zhe Liu, Pei-Xian Wu, Xiao-Ling Wei, Tian-Pei Hong. Inhibition of hepatic interleukin-18 production by rosiglitazone in a rat model of nonalcoholic fatty liver disease. World Journal of Gastroenterology 2008; 14(47): 7240-7246 doi: 10.3748/wjg.14.7240
|
| 32 |
Manal F. Abdelmalek, Anna Mae Diehl. Mechanisms underlying nonalcoholic steatohepatitis. Drug Discovery Today: Disease Mechanisms 2006; 3(4): 479 doi: 10.1016/j.ddmec.2006.11.001
|
| 33 |
O. Hussein, J. Zidan, K. Abu Jabal, I. Shams, S. Szvalb, M. Grozovski, I. Bersudsky, R. Karry, M. Aviram. Paraoxonase Activity and Expression Is Modulated by Therapeutics in Experimental Rat Nonalcoholic Fatty Liver Disease. International Journal of Hepatology 2012; 2012: 1 doi: 10.1155/2012/265305
|
| 34 |
Peter P Toth, Alberico Catapano, Joanne E Tomassini, Andrew M Tershakovec. Update on the efficacy and safety of combination ezetimibe plus statin therapy. Clinical Lipidology 2010; 5(5): 655 doi: 10.2217/clp.10.49
|
| 35 |
Hironori Nakagami, Mariana Kiomy Osako, Yoichi Takami, Rie Hanayama, Hiroshi Koriyama, Masaki Mori, Hiroki Hayashi, Hideo Shimizu, Ryuichi Morishita. Vascular protective effects of ezetimibe in ApoE-deficient mice. Atherosclerosis 2009; 203(1): 51 doi: 10.1016/j.atherosclerosis.2008.05.026
|
| 36 |
Theodosios D Filippatos, Moses S Elisaf. Role of ezetimibe in non-alcoholic fatty liver disease. World Journal of Hepatology 2011; 3(10): 265-267 doi: 10.4254/wjh.v3.i10.265
|
| 37 |
Kojiro Seki, Takanori Boku, Atsushi Umemura, Mika Matsumoto, Masayuki Mizuno, Toshihide Shima, Takeshi Okanoue. A case report of successful treatment with a cholesterol absorption inhibitor for decompensated burned-out NASH. Kanzo 2009; 50(9): 532 doi: 10.2957/kanzo.50.532
|
| 38 |
Tomonori Muraoka, Kazutaka Aoki, Tomoyuki Iwasaki, Kazuaki Shinoda, Akinobu Nakamura, Hiroyuki Aburatani, Shuuichi Mori, Kumpei Tokuyama, Naoto Kubota, Takashi Kadowaki, Yasuo Terauchi. Ezetimibe decreases SREBP-1c expression in liver and reverses hepatic insulin resistance in mice fed a high-fat diet. Metabolism 2011; 60(5): 617 doi: 10.1016/j.metabol.2010.06.008
|
| 39 |
Hemda Schmilovitz-Weiss, Edith Hochhauser, Michal Cohen, Yelena Chepurko, Smadar Yitzhaki, Ehud Grossman, Avshalom Leibowitz, Zvi Ackerman, Ziv Ben-Ari. Rosiglitazone and bezafibrate modulate gene expression in a rat model of non-alcoholic fatty liver disease - A historical prospective. Lipids in Health and Disease 2013; 12(1) doi: 10.1186/1476-511X-12-41
|